Skip to Main content Skip to Navigation
Journal articles

Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma.

Abstract : This study investigated the immunomodulatory effects of low-dose interferon-alpha (IFN-alpha) in a cohort of 21 stage II or III melanoma patients treated in an adjuvant setting. Serial assessments in peripheral blood were performed at baseline and at regular intervals. Depletion of CD3+CD4+ T cells was predominant within the "central memory" and "memory" subsets. The impact of IFN-alpha was more marked at the level of all CD3+CD8+ T-cell subsets that showed a sustained and significant decrease. Both myeloid and plasmacytoid dendritic cell (DC) subsets were depleted, but the MDC/PDC ratio tended to increase 12 months after treatment. Also, CD14+CD16+ monocytes showed a significant increase of both MHC class I and the CD86 costimulatory molecule. IP-10/CXCL10 plasma levels significantly increased already at 3 months of therapy and remained at significantly high levels during the study period. The dramatic increase of IP-10/CXCL10 inversely correlated with a significant decrease of the CXCR3+CD8+ T lymphocytes. Low-dose IFN-alpha therapy can significantly affect phenotypic and functional properties of blood circulating lymphocytes and antigen-presenting cells, and production of IP-10/CXCL10, that appear to be important for the orchestration of an effective immune response during adjuvant IFN-alpha therapy for melanoma.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00484535
Contributor : Philippe Saas <>
Submitted on : Tuesday, May 18, 2010 - 3:30:57 PM
Last modification on : Wednesday, September 16, 2020 - 10:43:29 AM

Identifiers

Collections

Citation

Anne-Marie Mohty, Jean-Jacques Grob, Mohamad Mohty, Marie-Aleth Richard, Daniel Olive, et al.. Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma.. Immunobiology, Elsevier, 2010, 215 (2), pp.113-23. ⟨10.1016/j.imbio.2009.03.008⟩. ⟨inserm-00484535⟩

Share

Metrics

Record views

278